title: Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.
abstract: OBJECTIVE
  To assess the effect of ranitidine on the pharmacokinetics of eprosartan in healthy male volunteers.
  
  
  METHODS
  Single-center, randomized, open-label, two-period, period-balanced, crossover study.
  
  
  METHODS
  Seventeen healthy men aged 19 to 43 years.
  
  
  METHODS
  In each period (separated by a > or = 7 d washout), subjects received a single 400-mg oral dose of eprosartan alone, or a single oral dose of eprosartan 400 mg and ranitidine 150 mg on day 4 after 3 days of ranitidine 150 mg twice daily. Serial pharmacokinetic samples were obtained for up to 24 hours following eprosartan dosing.
  
  
  METHODS
  Plasma and urine eprosartan concentrations during each treatment session.
  
  
  RESULTS
  Eprosartan maximum concentration (Cmax), the AUC from time-zero to the last quantifiable concentration (AUC0-t), and renal clearance (Cl(r)) values were approximately 7%, 11%, and 4% lower, respectively, when administered with ranitidine compared with eprosartan alone. The 95% CIs for the ratio of eprosartan plus ranitidine compared with eprosartan alone were 0.81 to 1.07, 0.77 to 1.03, and 0.64 to 1.43, for Cmax, AUC0-t, and Cl(r), respectively, indicating no statistically significant difference between regimens.
  
  
  CONCLUSIONS
  Repeated doses of ranitidine did not have a marked effect on the single-dose pharmacokinetics of eprosartan.
authors.affiliation: SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA.
authors.forename: D M
authors.initials: DM
authors.lastname: Tenero
authors.forename: D E
authors.initials: DE
authors.lastname: Martin
authors.forename: B E
authors.initials: BE
authors.lastname: Ilson
authors.forename: D A
authors.initials: DA
authors.lastname: Boyle
authors.forename: S C
authors.initials: SC
authors.lastname: Boike
authors.forename: A M
authors.initials: AM
authors.lastname: Carr
authors.forename: D E
authors.initials: DE
authors.lastname: Lundberg
authors.forename: D K
authors.initials: DK
authors.lastname: Jorkasky
mesh_terms: D000179:Acrylates / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D000284:Administration, Oral; D000328:Adult; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000959:Antihypertensive Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D019540:Area Under Curve; D018592:Cross-Over Studies; D006635:Histamine H2 Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D008297:Male; D011899:Ranitidine / Q000009:adverse effects / Q000494:pharmacology*; D013876:Thiophenes
chemical_list: D000179:Acrylates; D000959:Antihypertensive Agents; D006635:Histamine H2 Antagonists; D007093:Imidazoles; D013876:Thiophenes; D000804:Angiotensin II; C068373:eprosartan; D011899:Ranitidine